Tysabri

Tysabri
Fvasconcellos (talk · contribs) · Public domain · source
Name	Tysabri
Tradename	Tysabri
Drugs	natalizumab
Pregnancy category	C (Australia)
Routes of administration	Intravenous infusion
ATC prefix	L04
ATC suffix	AA23
Legal status	Prescription-only
CAS number	188466-40-6

Tysabri is a monoclonal antibody medication indicated primarily for relapsing forms of Multiple sclerosis and for moderately to severely active Crohn's disease. It is administered by intravenous infusion and developed to reduce inflammatory activity in neuroinflammatory and gastrointestinal autoimmune conditions. The drug is notable for efficacy in reducing relapse rates and preventing disability progression, as well as for associations with progressive multifocal leukoencephalopathy and regulatory actions.

Medical uses

Tysabri is approved for treatment of relapsing forms of Multiple sclerosis and for induction and maintenance therapy in moderately to severely active Crohn's disease in adults. Clinical trials compared Tysabri with placebo in trials involving patients meeting criteria from organizations such as the World Health Organization, European Medicines Agency, and Food and Drug Administration. Outcomes assessed included relapse rate reductions similar to results reported in landmark studies alongside cohorts described in literature by investigators affiliated with institutions like Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Mount Sinai Hospital, and Massachusetts General Hospital. Subpopulations studied included patients profiled in registries coordinated by groups like the National Institutes of Health, European Academy of Neurology, and American Academy of Neurology. Use considerations reflect guidance from specialty societies including the American Gastroenterological Association and the European Crohn's and Colitis Organisation.

Mechanism of action

Tysabri is a humanized monoclonal antibody that targets the alpha-4 subunit of integrins expressed on leukocytes, interfering with cell adhesion pathways implicated in lesion formation described in neuropathology reports from institutions such as Harvard Medical School, Stanford University School of Medicine, and University College London. The mechanism prevents leukocyte trafficking across the blood–brain barrier, a concept elaborated in studies from laboratories at Rockefeller University, Yale School of Medicine, and Columbia University Irving Medical Center. Integrin blockade reduces inflammation in tissues studied in research programs at Karolinska Institute, University of Oxford, University of Cambridge, and Imperial College London. The mechanism is discussed in context with other biologics developed by pharmaceutical companies like Biogen, Elan, Roche, and Genentech.

Dosage and administration

Standard dosing involves intravenous infusion every four weeks, with administration protocols similar to infusion regimens used in centers such as Cleveland Clinic, UCLA Health, Mount Sinai Hospital, and Northwestern Memorial Hospital. Premedication, infusion time, and monitoring align with practice advisories from organizations like the American Society of Clinical Oncology, European Society for Drug Research, and hospital formularies at Mayo Clinic and Johns Hopkins Hospital. Patient selection often requires screening tests implemented by reference laboratories associated with Quest Diagnostics and LabCorp and documentation aligned with guidance from payers including Centers for Medicare & Medicaid Services and health technology assessment bodies such as NICE.

Adverse effects and safety

Major safety concerns include risk of progressive multifocal leukoencephalopathy, a demyelinating infection caused by the JC virus identified in virology reports from institutions like CDC, NIH, and European Centre for Disease Prevention and Control. Safety monitoring includes serologic testing strategies developed in collaboration with laboratories such as Mayo Clinic Laboratories and surveillance programs driven by regulators including the Food and Drug Administration and the European Medicines Agency. Infusion-related reactions, immune reconstitution inflammatory syndrome, and opportunistic infections have been reported in case series published by centers like Massachusetts General Hospital, Johns Hopkins Hospital, and Toronto General Hospital. Risk management plans mirror those used for other immunomodulators discussed in reviews from Lancet, New England Journal of Medicine, and JAMA. Long-term safety registries include contributions from networks such as the MSBase registry and investigator consortia at Karolinska Institute.

Regulatory status and history

Developed by companies including Biogen and Elan, the medication underwent pivotal randomized trials conducted at academic sites like University of California, San Francisco, Duke University Medical Center, and University of Pennsylvania Perelman School of Medicine. After initial approval processes with the Food and Drug Administration and post-marketing surveillance prompted by reports compiled by the CDC and WHO, regulators instituted risk evaluation and mitigation strategies. The European Medicines Agency and national agencies such as Health Canada and the Therapeutic Goods Administration implemented labeling and access programs. Historical milestones include clinical development phases overseen by investigators linked to Harvard Medical School and trial networks funded in part by entities like the National Multiple Sclerosis Society and industry partners.

Pharmacology and interactions

Pharmacokinetic and pharmacodynamic profiles were characterized in studies at institutions including Vanderbilt University Medical Center, University of Michigan, and Penn Medicine. Interactions with other immunosuppressants and biologics such as agents developed by companies like AbbVie, Pfizer, and Janssen require caution and are discussed in consensus statements from American College of Rheumatology and European Crohn's and Colitis Organisation. Concomitant therapies used in multiple sclerosis and Crohn's disease management—agents referenced in guidelines by NICE, AAN, and AGA—influence infection risk and immunogenicity monitoring advised by laboratories like Quest Diagnostics. Vaccine timing and live vaccine contraindications reflect recommendations from CDC and specialist societies such as Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases.

Category:Monoclonal antibodies Category:Multiple sclerosis drugs Category:Crohn's disease treatments